In Patients with Established RA, Positive Effects of a Randomised Three Month WBV Therapy Intervention on Functional Ability, Bone Mineral Density and Fatigue Are Sustained for up to Six Months by Prioreschi, A. et al.
RESEARCH ARTICLE
In Patients with Established RA, Positive
Effects of a Randomised Three Month WBV
Therapy Intervention on Functional Ability,
Bone Mineral Density and Fatigue Are
Sustained for up to Six Months
Alessandra Prioreschi1,2*, Mohamed A. Makda3, Mohammed Tikly3, Joanne A. McVeigh1
1 Exercise Physiology Laboratory, School of Physiology, Faculty of Health Sciences, University of the
Witwatersrand, Johannesburg, South Africa, 2 Department of Paediatrics, MRC/Wits Developmental
Pathways for Health Research Unit, University of theWitwatersrand, Johannesburg, South Africa, 3 Division
of Rheumatology, Department of Medicine, Chris Hani Baragwanath Academic Hospital, University of the
Witwatersrand, Johannesburg, South Africa
* alessandraprioreschi@gmail.com
Abstract
Functional ability is often impaired for people with rheumatoid arthritis (RA), rendering these
patients highly sedentary. Additionally, patients with RA often take medication known to
negatively affect bone mass. Thus improving functional ability and bone health in this group
of patients is important. The aim of this study was to investigate the effects of whole body
vibration (WBV) therapy in patients with stable, established RA. Thirty one females with RA
were randomly assigned to a control group (CON, n = 15) who continued with their normal
activities or a WBV group (n = 16) who underwent a three month WBV therapy intervention,
consisting of 15 minutes of intermittent vibration, performed twice per week. Patients were
assessed at baseline, three months, and three months post intervention for functional ability
using the modified Health Assessment Questionnaire; for RA disease activity using the Clin-
ical Disease Activity Index, for quality of life using self-report fatigue and pain scores; for
physical activity profiles using accelerometry, and for BMD and body composition using
DXA. Patients in both groups were matched for all variables at baseline. After the interven-
tion period, functional ability was significantly improved in the WBV group (1.22(0.19) to
0.92(0.19), p = 0.02). Hip BMD was significantly reduced in the CON group (0.97(0.05) to
0.84(0.05) g.cm-2, p = 0.01), while no decreases were seen in the WBV group (1.01(0.05) to
0.94(0.05) g.cm-2, p = 0.50). Despite no change in RA disease activity in either group at
either follow up, fatigue levels were improved in the WBV group (4.4(0.63) to 1.1(0.65), yet
remained unchanged in the CON group at both follow ups (p = 0.01). Ten minute bouts of
light to moderate physical activity were significantly reduced in the CON group after the
intervention (2.8(0.61) to 1.8(0.64) bouts per day, p = 0.01), and were preserved in the WBV
group (3.1(0.59) to 3.0(0.61) bouts per day, p = 0.70). Intermittent WBV shows promise for
sustained improvements in functional ability, for attenuating loss of bone mass at the hip, as
well as for decreasing fatigue in patients with established RA.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune condition with a predilection for peripheral
synovial joints. Inadequate or poor control of inflammation results in chronic pain, joint
destruction, and decreased functional ability. Osteoporosis and osteopenia are common in
patients with RA, and a variety of factors predispose RA patients to rapid loss of bone, includ-
ing pro-inflammatory cytokines that augment osteoclast activity, certain medications taken to
treat the disease such as oral corticosteroids, and decreased mobility. Levels of mobility and
functional ability have been shown to be related to bone mineral density (BMD), as have age,
stature, and sex, independently of RA disease [1], [2].
Moderate and vigorous habitual physical activities have known osteogenic effects [3]. Con-
versely, increased time spent in sedentary behaviours has been independently associated with
poor bone mass in healthy populations [4]. Patients with RA spend the majority of their day
being sedentary [5]. Furthermore, a large qualitative study conducted in female patients with RA
found that patients reported pain and decreased functional ability as having the most widespread
effect on their daily lives [6]. Inability to perform normal daily activities not only decreases quality
of life, but also further perpetuates a sedentary lifestyle. Functional ability as assessed by the
Health Assessment Questionnaire (HAQ), has been shown to be improved following certain exer-
cise interventions conducted in patients with RA [7], yet there is still no consensus on the most
feasible type of exercise intervention for patients with chronic pain and, often severe disability.
The beneficial effects of both aerobic and resistance exercise interventions to the health of
patients with RA has been proven [8], yet exercise interventions in RA are not always feasible,
specifically bone loading exercises which need to be dynamic in order to increase bone mass
[9]. Whole body vibration (WBV) is safe, and requires minimal effort and movement [10]. The
vibratory waves generated by a mechanical vibration platform produce energy via forced oscil-
lation, which is then transferred to an individual via propagation through the feet, legs, trunk
and the head [11]. WBV therapy has been shown to decrease fatigue and pain levels, and to
improve muscle strength in patients with fibromyalgia [12], [13], and to decrease pain levels in
patients with knee osteoarthritis [10], as well as to increase strength and balance, in various
chronic conditions [14]. Furthermore, studies conducted in postmenopausal women [15], as
well as in younger healthy populations [16], and athletes with low BMD [17] have shownWBV
therapy to improve BMD, particularly at the hip and spine [18], [19].
WBV therapy has not, to the best of our knowledge, been used as a form of exercise in
patients with RA. Furthermore, of the studies that have used WBV therapy in other popula-
tions, none have examined whether WBV therapy induced effects are sustained post interven-
tion. The primary aim of this study was to determine the effects of a WBV programme on
functional ability in patients with established RA. Secondly, the study aimed to determine any
effects WBV therapy may have on BMD, RA disease activity, indices of health related quality
of life (HRQoL), physical activity profiles, and body composition.
Patients and Methods
Study design
In this longitudinal study, consenting female patients were assigned (using an alternating
method) to either a WBV group who underwent the WBV therapy, or a control (CON) group
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who continued with their normal daily activities. Following a baseline assessment (assessment
1), patients underwent the relevant intervention (WBV therapy or normal activity) for a three
month period, following which all patients returned for a follow up assessment (assessment 2)
in order to determine the effects of the WBV therapy intervention in comparison to the CON
group. Thereafter, all patients continued with their normal activities for a further three months,
following which a three month post intervention assessment was conducted (assessment 3) in
order to determine whether any WBV therapy effects were sustained. Patients were enrolled
from April to August 2013, the first follow up was completed for all participants by November
2013, and the final follow up for all participants was completed by the end of February 2014.
The full protocol for this study has been published elsewhere [20]. The study protocol and
CONSORT checklist can be found in the supporting information: S1 Text and S2 Text. The
trial registration information for this study is PACTR201405000823418 (19/05/2014) and is
available as S3 Text. This trial was only registered after data collection commenced as the pro-
tocol was first piloted for feasibility before registration.
Patients
Thirty nine adult female patients who met the 1987 American College of Rheumatology classi-
fication criteria [21], had established disease of at least three years duration, and were on stable
drug therapy (prednisone <10mg/day) for at least three months were included in the study.
Patients were recruited and assessed at the Chris Hani Baragwanath Academic Hospital and
gave written informed consent to be included in the study. Exclusion criteria were known HIV
disease, use of bisphosphonates for the treatment of osteoporosis, any co-morbidities that
could potentially impact on physical activity levels, use of assistive walking devices, previous
hip or knee joint replacement surgery or arthroplasty, and pregnancy. Ethical approval was
obtained from the Human Research Ethics Committee of the University of the Witwatersrand
(M130113), and this trial conforms to the guidelines set out in the Declaration of Helsinki.
Whole body vibration therapy intervention
Whole body vibration therapy consisted of two 15 minute session per week (total of 24 sessions
over 12 weeks) of supervised therapy, which comprised of ten repetitions standing on the
vibration plate for 60 seconds, followed by a 30 second rest period. This intermittent protocol
was designed to increase osteogenic effects [22] and has previously been used successfully [17].
All WBV training was performed on the same vertical synchronous vibration plate (DKN XG
5.0, DKN Technology, California, USA). Different vibration platforms exist; vertical synchro-
nous platforms move both legs up and down in unison, while oscillating plates move each leg
up and down in a side-alternating manner. Vertical plates have most often been used to pro-
duce anabolic effects at the hip and spine as transmission of frequencies is site specific (vertical
transmissions move in a vertical plane while side-alternating transmissions move in a more lat-
eral plane); and accelerations produced are generally greatest at anatomical sites closest to the
vibration platform [23]. Vibration was set at 3mm amplitude and a frequency of 30Hz in all
instances, as lower amplitude, higher frequency vibrations have been shown to elicit greater
responses in bone [24], and similar frequencies and amplitudes have been used in patients with
fibromyalgia [14]. Patients were taught the correct posture (barefoot, holding on to the handle
bars with knees slightly bent) while on the vibration plate in order to maximise the vibration
effect while minimising any harmful effects, and to standardise procedure. All sessions were
monitored by the primary investigator (AP) for compliance and accuracy. The CON group
was instructed to continue with their normal daily activities for the three month period.
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Outcome assessments
Functional ability assessment. All patients were assessed at each time period for func-
tional ability using the modified Health Assessment Questionnaire (mHAQ). The mHAQ is a
well validated, self-administered, RA specific questionnaire that assesses functional ability in
eight domains of daily activities where scores range from 0 (no disability) to 3 (severe disabil-
ity) [25].
Disease activity and HRQoL measurements. All patients were assessed at each time point
for rheumatoid disease activity using the Clinical Disease Activity Index (CDAI) by the same
physician (MAM, who was blinded to the assignment of patients to either the WBV group or
CON group). Patients were also asked to self assess their fatigue levels using a Lickert scale
anchored at 0 (not tired at all) and 5 (the most tired I have ever felt), as well as their pain
anchored at 0 (no pain) and 5 (unbearable pain).
Physical activity. Patients were fitted with an Actical (Respironics Inc., Murrysville, PA,
USA) accelerometer worn on a Velcro belt on the right hip for a one week period at baseline, as
well as at assessments 2 and 3 for the assessment of habitual physical activity. Patients then
returned the accelerometer to the clinic one week later. Patients were instructed to wear the
accelerometer all day, and to remove the device only while sleeping, bathing or showering.
Actical data were recorded in one minute epochs and data were reduced by removing full days
of non-wear time as observed by a full day of zero activity counts. Sleep time was removed by
direct observation of the data [26], and only the remaining data were considered as wear time.
Three days of wear time with a minimum of 10 hours of wear time per day was required for
inclusion in the analysis [27].
Activity data. The Actical accelerometer records activity counts, which, based on the
number of counts per epoch, are then classified by the inbuilt Actical software into thresholds
of intensity; namely sedentary (0–100 counts), light activity (101–1485 counts), moderate
activity (1486–5557 counts), and vigorous activity (5558 counts). Data were thus considered
“active” data if a minute epoch had an activity count that was greater than 100 (i.e.: light to
moderate/vigorous activity). Activity bouts were then calculated as the number of times per
day that at least 10 consecutive minutes of “active data” were recorded [28]. The number of
times that sedentary activity was “broken up” was calculated as the number of times per day
that a sedentary minute epoch (<101 counts) was followed by at least one active minute epoch
(>100 counts); and these data were thus considered as a break in sedentary time [29]. Data
were reported as average activity counts per day; percentage of time spent in sedentary, light,
moderate and vigorous activity thresholds; average number of activity bouts per day, as well as
average number of sedentary breaks per day. Patients wore the same Actical at both visits in
order to minimise inter-device variability.
BMD assessment. At each time point, patients underwent a Dual X-Ray Absorptiometry
(DXA) scan to assess BMD and body composition. All patients were assessed for site specific
areal BMD at the left hip, lumbar spine (L1-L4), and whole body. A single DXA operator was
used throughout the study and was blinded as to the assignment of the patients to the WBV or
CON group. A single machine was used (Hologic QDR 4500A, Hologic, Boston, USA), and
was routinely calibrated throughout the study, using a phantom spine that was scanned daily
to determine coefficients of variation of the machine. The coefficient of variation during the
course of the study for spine BMD was 0.31%.
Body composition. At each time point, height (measured to the nearest mm using a stadi-
ometer (Holtaine, UK)), and body mass (measured to the nearest 100g using a standard digital
scale (Dismed, USA) were measured. From these measurements Body Mass Index (BMI) was
calculated. Total lean and fat mass measurements were obtained from the body composition
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component of the whole body DXA scan. Skeletal muscle index (SMI) was calculated by adding
appendicular lean mass (left and right- arm and leg- lean masses), and dividing by height
squared [30].
Statistical analysis
All analyses were conducted using Stata 12/IC 12.0 for Mac (StataCorp LP, College Station TX,
USA) and p value of< .05 was considered statistically significant. A two sided sample size cal-
culation for means with repeated measures (ß = 0.10) showed that at a 5% level (using an SD of
0.19) a sample of 8 patients in each group would be required in order to detect a minimum
clinically important difference of 0.22 in mHAQ score [31] with a power of 90%. Students
unpaired t-tests were used to compare continuous variables between the WBV group and CON
group at baseline. Thereafter, to assess the effect of the intervention on the primary and sec-
ondary outcomes, individual linear mixed models were used for each dependent variable. Ran-
dom intercepts were used to account for within person correlation of repeated measures and
missing data as per an intention to treat analysis. To test a priori hypothesis, the estimated
mean scores at each time point (three- and six months post baseline) were contrasted with
baseline values for main effects, and group by time interactions as well as 95% confidence inter-
vals (CI) were calculated. Model fit was assessed using residual plots and diagnostics. Percent-
age change from baseline was calculated and compared between groups using Students
unpaired t-tests. All continuous variables are expressed as means and standard deviations (SD)
or means and standard error of the means (SEM).
Results
Patient characteristics
Following enrollment, eight patients were excluded due to not being able to attend the required
assessments. These patients were no different from completers in terms of age, disease dura-
tion, or functional ability (all p>0.05). Hence, 31 patients were allocated to the WBV group
(n = 16) or the CON group (n = 15) and completed the three month intervention, however at
assessment 3, one patient in the WBV group and three patients in the CON group were lost to
follow up due to no longer being interested in participating, or not being able to attend the
required assessments (Fig 1). Data can be found in the supporting information: S1 Data.
At baseline, there were no differences between the WBV group and the CON group for any
of the variables measured as shown in Table 1. There were no differences between the WBV
and CON groups for BMD at any of the sites measured at baseline (data shown in Table 2).
Furthermore, there were no differences between the WBV and CON groups for average physi-
cal activity levels (p = 0.63, data shown in Table 2). Baseline (assessment 1), post intervention
(assessment 2), and six month follow up (assessment 3) data for mHAQ, BMD, RA disease and
physical activity variables are presented in Table 2.
Functional ability
In the WBV group, mHAQ (where a lower score indicates an improved outcome) was
improved (p = 0.02, CI -0.55 to -0.05) at assessment 3 as compared to baseline, while no
changes were observed in the CON group at either assessment 2 or 3. Fig 2 shows the mean
change in mHAQ between the two groups from baseline at each assessment. Of patients who
underwent WBV therapy, 63% showed an improvement in mHAQ, while 60% of patients in
the CON group showed a worsened mHAQ score over the three month intervention period.
The Effects of a Three Month WBV Therapy Intervention in RA
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HRQoL and disease activity
Table 2 shows the time effect (p = 0.04), as well as a group by time interaction (p = 0.01) for
fatigue levels, where fatigue was decreased (p<0.01, CI -4.82 to -1.67) in the WBV group at
assessment 2 as compared to baseline, however this effect was not sustained at assessment 3.
No changes were observed in the CON group for fatigue levels over the study period. Fig 3
Fig 1. Number of study patients initially enrolled and followed up at each assessment time point.
doi:10.1371/journal.pone.0153470.g001
Table 1. Patient characteristics at baseline in theWBV group and CON group. Data are mean (SD).
WBV (n = 16) CON (n = 15) p value
Age (years) 51(10) 52(12) 0.81
Disease duration (years) 10(11) 12(8) 0.54
Height (m) 1.59(0.07) 1.55(0.08) 0.16
Body mass (kg) 85.24(21.96) 80.76(23.63) 0.59
CDAI 11(9) 8(6) 0.33
mHAQ (max. of 3) 1.22(0.67) 1.13(0.86) 0.74
Pain (max. of 5) 4(3) 4(3) 0.92
Fatigue (max. of 5) 4(3) 3(3) 0.35
Lean body mass (kg) 45.65(8.48) 42.11(7.96) 0.25
% body fat 42(7) 41(6) 0.55
CDAI–clinical disease activity index, mHAQ–modified health assessment questionnaire.
doi:10.1371/journal.pone.0153470.t001
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shows the percentage change in fatigue scores for each individual at the post intervention
assessment as compared to baseline. Percentage change showed a trend towards being signifi-
cantly greater in the WBV group compared to the CON group (p = 0.06). There were no
changes in CDAI scores over the intervention period for either of the groups. There were no
changes in pain levels over the study period for either of the groups.
Physical activity
No main effects, or group by time interactions were observed for physical activity levels
(Table 2). No changes were evident in either group for average activity counts per day, or
Table 2. Mixedmodel analysis between theWBV and CON groups at baseline, three- and six month assessments. Data are mean (SEM).
WBV CON Mixed models analysis (p
value)





















Fatigue (/5) 4.4(0.63) 1.1(0.65)* 3.7(0.67) 3.4(0.67) 3.7(0.75) 3.7(0.72) 0.40 0.04 0.01
Pain (/5) 3.90(0.69) 3.07(0.71) 4.75(0.71) 4.00(0.71) 4.83(0.71) 4.75(0.78) 0.40 0.34 0.26





7296(828) 7424(864) 7194(884) 6984(855) 6613(855) 6385(971) 0.53 0.85 0.88
Sedentary
(%/day)
68(2.6) 68(2.8) 70(2.8) 69(2.7) 70(2.8) 71(3.2) 0.67 0.57 0.96
Light(%/day) 21(1.70) 21(1.80) 19(1.85) 20(1.75) 20(1.75) 20(2.08) 0.80 0.65 0.92
Moderate
(%/day)
11(1.27) 11(1.32) 10(1.35) 11(1.31) 10(1.31) 9(1.47) 0.59 0.50 0.91
Vigorous
(%/day)








3.1(0.59) 3.4(0.60) 3.0(0.61) 2.8(0.61) 2.1(0.61)* 1.8(0.64)* 0.26 0.14 0.16
Bone Hip BMD (g.
cm2)
1.01(0.05) 0.96(0.05) 0.94(0.05) 0.97(0.05) 0.94(0.05) 0.84(0.05)* 0.37 0.01 0.50
Spine BMD
(g.cm2)
0.92(0.04) 0.92(0.04) 0.92(0.04) 0.91(0.04) 0.91(0.04) 0.91(0.04) 0.87 0.84 0.74
Whole Body
BMD (g.cm2)
1.09(0.03) 1.10(0.03)^ 1.10(0.03)* 1.07(0.03) 1.07(0.03) 1.05(0.03)* 0.47 0.15 <0.01
Body
Composition
BMI (kg/m2) 34(2.1) 34(2.1) 33(2.1)* 34(2.2) 34(2.2) 34(2.2) 0.84 0.58 0.05
Fat mass
(kg)
37(3) 36(3) 35(3)* 31(3) 32(3) 35(3)* 0.43 0.44 <0.01
Lean mass
(kg)
46(2) 46(2) 45(2) 42(2) 42(2) 40(2)* 0.13 <0.01 <0.01
SMI 7.8(0.39) 8.0(0.39)^ 8.0(0.39)^ 7.7(0.40) 7.9(0.40)* 7.4(0.41)* 0.64 0.02 <0.01
Breaks in sedentary time are adjusted for % total sedentary time at each time point.
mHAQ–modified health assessment questionnaire, HRQoL–health related quality of life, CDAI–clinical disease activity index, AC–activity counts, BMD–
bone mineral density, BMI—body mass index, SMI–skeletal mass index.
* Main effects significantly different from baseline after posthoc analysis (p<0.05).
^ Main effects showed trend towards significant difference from baseline after posthoc analysis (p<0.07).
doi:10.1371/journal.pone.0153470.t002
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Fig 2. Change in functional ability. Assessed by the modified Health Assessment Questionnaire (mHAQ) from baseline to post intervention (three month
assessment) and six month follow up between the whole body vibration group (WBV) and the control group (CON).
doi:10.1371/journal.pone.0153470.g002
Fig 3. Percentage change in fatigue. From baseline to post intervention (three month assessment) for each
participant in the whole body vibration group (WBV) and the control group (CON) where a negative change
indicates less fatigue. Percentage change was greater in the WBV group (p = 0.06).
doi:10.1371/journal.pone.0153470.g003
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percentage of time spent in sedentary, light, moderate or vigorous activity over the study
period. However, in the CON group, there were fewer breaks in sedentary time (after adjusting
for percentage of time in sedentary activity at each time point) (p = 0.05) at assessment 2 as
compared to baseline. In the CON group, there was also a decrease (p = 0.05, CI -1.79 to -0.16)
in number of activity bouts per day at assessment 2 as compared to baseline; and this effect was
sustained at assessment 3 compared to baseline assessment (p = 0.01). No changes were
observed in the WBV group for number of breaks in sedentary time, or number of active bouts.
Bone mineral density
Hip BMD was lower (p = 0.01, CI -0.23 to -0.03) in the CON group at assessment 3 compared to
baseline. No changes were observed for the WBV group. There were no changes in spine BMD
over the study period for either of the groups. A time and group interaction was evident for
whole body BMD (p<0.01), whereby there was a trend towards a significant (p = 0.06) increase
in whole body BMD for the WBV group at assessment 2, and BMD was further increased at
assessment 3 compared to baseline (p = 0.05, CI -0.01 to 0.01) (Table 2). In the CON group,
whole body BMD was decreased (p<0.01, CI -0.02 to -0.002) at assessment 3 compared to base-
line. When comparing the two groups at assessment 3, theWBV group showed improvement in
whole body BMD by an average of (0.90(0.53)%) compared to the CON group, who on average
lost 0.66(0.52)%, p = 0.04). Fig 4 shows percentage change in whole body BMD at six months
Fig 4. Percentage change in whole body bonemineral density. From baseline to six month follow up for
each participant in the whole body vibration group (WBV) and the control group (CON) where a positive
change indicates improved BMD. Percentage change was greater in theWBV group (p<0.001).
doi:10.1371/journal.pone.0153470.g004
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compared to baseline for each participant. TheWBV group showed sustained improvements,
while the CON group showed sustained losses in whole body BMD (p<0.001).
Body composition
Table 2 shows the group by time interaction effects for BMI (p = 0.05) and fat mass (p<0.01),
both were decreased in the WBV group at assessment 3 as compared to baseline (p = 0.02, CI
-1.20 to -0.08 and p = 0.01, CI -3794.93 to -416.50 respectively). In the CON group, fat mass
increased (p<0.01, CI 1637.79 to 5830.64) at assessment 3 compared to baseline. Lean mass
and SMI showed time effects (p<0.01, and p = 0.02 respectively), as well as group by time
interactions (both p<0.01). Lean mass was decreased (p<0.01, CI -3363.64 to -1167.29) in the
CON group at assessment 3 as compared to baseline. SMI showed a trend towards significant
increase (p = 0.06) in the WBV group at assessment 2 from baseline, which was sustained at
assessment 3 from baseline (p = 0.08), while in the CON group SMI was decreased (p<0.01, CI
-1508.21 to -205.49) at assessment 2 from baseline, and at assessment 3 from baseline
(p = 0.02, CI -1790.77 to -488.05).
Discussion
The three month WBV therapy intervention in patients with RA had positive effects on func-
tional ability, HRQoL, physical activity profiles, BMD and body composition. Importantly,
mHAQ scores started to improve in patients who underwent the three month WBV therapy
intervention, and were significantly improved at the six month follow up. Also of importance
is the maintenance of whole body BMD observed in the WBV group after cessation of WBV
therapy, as well as the attenuation of loss of hip BMD in the WBV group in comparison to the
losses of hip BMD observed in the control group. The findings presented in the current lend
support to the possibility that WBV therapy may be useful for increasing functional ability, as
well as having a protective effect of bone health in patients with RA.
Improvements in activities of daily living as assessed by the mHAQ, is one of the key out-
come measures of RA treatment [32]. The majority of patients (63%) who underwent WBV
therapy showed either no change, or improvements in mHAQ scores. The overall improve-
ment in mHAQ scores following the passive exercise programme used in the present study is
comparable with those observed following active exercise interventions in groups of people
with RA, which utilised either strength training [33], [34], or aerobic exercise programmes
[35]. A WBV therapy intervention could therefore be a feasible means to improve the ability of
these patients to perform their normal daily activities, thereby greatly increasing their sense of
well being. WBV therapy has been shown to improve anti-inflammatory status in an elderly
population [36], which may impact patient’s ability to function normally. Improvements in
functional ability may also provide some protective effect on bone health in patients with RA,
by allowing patients to be more mobile and thus potentially less sedentary.
Fatigue and ‘feeling well’ are important and relevant outcomes from the patient perspective
in RA, and two of the most relevant improvements to note following treatment interventions
in RA [32], [37]. Despite RA disease activity remaining unchanged following the WBV therapy
intervention, fatigue levels were significantly improved by 53% (however these effects were not
maintained at the six month follow up). The positive effects of WBV therapy on fatigue are
similar to those observed in a cohort of patients with fibromyalgia who underwent a 6 week
mixed WBV and exercise intervention where decreases in fatigue levels, as well as pain levels
were observed, compared to a group that underwent exercise alone, and a control group where
no changes were observed [12]. Another study conducted in patients with osteoarthritis also
used a mixed exercise andWBV programme and were able to elicit improvements in pain
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levels over 8 weeks [10]. Moreover, WBV therapy in the present study has shown similar effects
on well being as have aerobic and resistance exercise interventions in RA in previous studies
[7], [35], [38].
Previous research has shown that higher levels of habitual physical activity in patients with
RA are correlated with improved fatigue levels, as well as functional ability [5]. Recent litera-
ture has focused on the beneficial effects of breaking up sedentary time on health, regardless of
overall activity levels [39], as well as the beneficial effects of being more active (often requiring
activity to be performed in 10 minute bouts) [40]. Although overall physical activity remained
unchanged before and after the intervention for both groups, there were important changes
observed in the patterns of physical activity that should be considered. The CON group
decreased the number of times they broke up their sedentary time and also had fewer bouts of
activity following the intervention signifying more time spent in prolonged period of uninter-
rupted sedentary time in this group, yet activity profiles were maintained in the WBV group
throughout the intervention period. Limiting sedentary time has been shown to have beneficial
effects on bone health [4]. It is possible that the WBV therapy intervention, by means of
decreasing fatigue levels, allowed patients to modify their habitual physical activity profiles and
to start engaging in less sedentary behaviours, thereby becoming more functional.
In an RA population, where bone health is often compromised and increasing the risk of
fractures, maintenance of BMD is an important secondary goal of treatment. In the present
study it was found that WBV therapy improved whole body BMD in most patients (non signif-
icant average 8% increase from baseline), and that this effect was carried forward for a further
three months (significant average 9% increase from baseline). WBV therapy also preserved hip
BMD levels, while the CON group experienced losses in BMD at both the hip (-13%) and
whole body (-1%) over the six month period. The loss of hip BMD in the CON group was
greater than the least significant change needed for clinical relevance of 0.02g.cm2 at the hip
(0.04g.cm2 is needed at the spine [41]). As expected in a group of women with RA, the WBV
group also experienced clinically relevant decreases in hip BMD, yet these were much smaller
and non significant. Healthy participants of a similar age range have been shown to lose 3%
BMD at the hip over one year [42], and the NHANES database values for healthy women
between 40–50 years shows approximately 5% decrease over 10 years [43]. Hip BMD has been
shown to be the best predictor of fracture risk at any site [44], and WBV therapy may thus be
considered as an adjunct therapeutic option for counteracting the very rapid loss of BMD that
occurs in women with RA.
We, and others, have previously shown that WBV therapy improves or maintains BMD to
varying degrees, particularly at the hip and spine. Versheuren et al in 2004 [19] and Rubin et al
in 2004 [18] showed that WBV training for a six month and a one year period respectively, was
able to significantly increase hip BMD by up to 0.93% (and 1.37% in only compliant partici-
pants) in a group of postmenopausal women. Rubin and colleagues further showed improve-
ments in spine BMD of 0.49% in the compliant subset of their cohort. Prioreschi et al in 2012
were also able to show increases in hip BMD of 1.65%, and attenuated losses of spine BMD in a
group of road cyclists who participated in only 10 weeks of intermittent WBV therapy [17].
Some studies have found no effects of WBV therapy on bone [23], however confounding vari-
ables such as Vitamin D and calcium supplementation in the control group, young age of par-
ticipants, use of oscillating platforms, and lack of an intermittent protocol could explain the
lack of osteogenic effects observed in these studies. Site specific differences in BMD changes
evident between studies may also be due to transmission of frequencies along differing axes
due to the type of vibration plate used, and the amount of acceleration produced dependant on
frequency and amplitude settings. WBV therapy was well tolerated by the present cohort, and
could potentially be a feasible intervention for BMD in patients with RA that does not require
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the vigorous, high-impact movements that are usually required to increase BMD (yet are often
not feasible in this population). Although the exact mechanisms whereby WBV increases BMD
remain unclear and depend on the frequencies and amplitudes utilised, it is likely that there are
multiple mechanisms at play. Whole body vibration has been shown to activate fluid flow in
the caniliculi and lacunae of bone matrix in rats [45], in a manner proportional to loading fre-
quency, creating a shear stress on the plasma membrane of osteocytes, bone lining cells, and
osteoblasts, which may respond accordingly [9]. However, Uzer et al., (2013) showed that in
vitro fluid shear did not regulate vibration induced proliferation, and that cytoskeletal actin
remodeling may play a greater role [46]. WBV activates mechanotransduction in bone and can
stimulate osteogenesis [45], and low magnitude, high frequency vibration has been shown in
vitro to upregulate osteoblast differentiation, matrix synthesis and mineralization, while regu-
lating osteoclastic activity [24]. Furthermore, muscle forces exert osteogenic stimulus on bone,
and the generation of these forces through vibration stimulus is a likely contributor to the skel-
etal adaptations that occur [47].
Although the frequency used in this study was chosen to achieve osteogenic effects, WBV
therapy in this study also had a positive impact on body composition, lending support to the
use of frequencies of 30Hz for affecting body composition. The WBV group in this study lost a
significant amount of body mass (specifically -5% body fat) during the intervention period,
maintained their lean muscle mass, and showed a trend towards improving SMI (an indicator
of sarcopenia), while both SMI and lean mass were decreased in the CON group by 5% and 4%
respectively. Sarcopenia, in combination with osteoporosis, greatly increases the risk of obtain-
ing a fracture [48]. Whole body vibration has previously been shown to decrease BMI, and
body fat (as measured by DXA) in obese women [49], to improve muscle strength in women
with fibromyalgia [15], and to slow fat acquisition in rodent models [50]. This may be related
to the ability of WBV therapy to increase oxygen consumption, energy expenditure, and neuro-
muscular performance [51] through continuously effecting eccentric and concentric muscular
contractions [49], however higher frequencies are usually needed to elicit these effects. It is pos-
sible that the relatively low levels of habitual activity in this cohort allowed for changes in
energy expenditure and thus body composition, even with lower frequencies of vibration.
Alternatively, the simple participation in an organised activity twice weekly may have result in
greater energy expenditure than normal. In both of the aforementioned studies a decrease in
fat mass following WBV was mirrored by an increase in BMD or bone mineral content, which
was not observed in the relevant control group. Although lower body mass is a known risk fac-
tor for low bone mass [52], and it is therefore assumed that higher body mass is protective of
BMD, recent studies have suggested that obesity may have an inverse relationship with BMD
[53], and that fractures that occur in obese populations should be considered ‘fragility frac-
tures’ [54]. Potentially, obesity is distinct from ‘high body mass’ in terms of the effect it has on
bone health; and should still be avoided in patients with RA, as is recommended in the general
population. These results suggest that WBV therapy may be useful in decreasing body mass, as
well as increasing lean muscle mass in patients with RA.
This study has strengths and limitations. The results showed that many of the benefits of
WBV therapy in patients with RA can be sustained for at least three months post therapy. Fur-
thermore, attrition rates were low, suggesting that the WBV program was well tolerated within
this population. Unfortunately no qualitative assessments of the intervention were made, and
thus the possibility that group participation had an effect on various outcomes cannot be
negated. Since the intervention ran over a year period with staggered recruitment, the effects of
the colder temperatures in winter may have altered various pain and well-being outcomes;
however patients were recruited in an alternating manner, which would limit the potential dif-
ferences between groups. Vitamin D, calcium intake and menopausal status were unfortunately
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not controlled for, which may have confounded changes in bone density. Furthermore, the
small sample size and limited duration of the intervention must be considered.
In conclusion, the findings of this study show that a WBV therapy intervention can illicit
sustained improvements in functional ability in females with RA. Bone mass at the hip and
whole body was preserved, as was lean muscle mass. Patients who participated in the WBV
therapy intervention also had improved fatigue levels without any changes in RA disease activ-
ity being observed. Furthermore, patients in the WBV group maintained their habitual physical
activity profiles throughout the assessment period. Based on these findings, it seems that WBV
therapy offers a useful and affordable adjunct therapy with sustained effects for patients with
established RA, which does not require vigorous, high-impact movements. Future studies
including qualitative assessments need to be conducted over a longer duration in a larger
cohort of both males and females.
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